1)Kirchhoff C, Habben I, Ivell R, et al:A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 45:350-357,1991
2)Galgano MT, Hampton GM, Frierson HF Jr:Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19:847-853,2006
3)Moore RG, McMeekin DS, Brown AK, et al:A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112:40-46,2009
4)Sturgeon CM, Duffy MJ, Stenman UH, et al:National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54:e11-e79,2008
5)Buamah P:Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 75:264-265,2000
6)Ferraro S, Braga F, Lanzoni M, et al:Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol 66:273-281,2013
7)Drapkin R, von Horsten HH, Lin Y, et al:Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65:2162-2169,2005
8)Moore RG, Brown AK, Miller MC, et al:The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108:402-408,2008
9)Chan KK, Chen CA, Nam JH, et al:The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol 128:239-244,2013
10)Sandri MT, Bottari F, Franchi D, et al:Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol 128:233-238,2013
11)Anastasi E, Marchei GG, Viggiani V, et al:HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 31:113-119,2010